Borella L, Sen L, Casper J T
J Immunol. 1977 Jan;118(1):309-15.
Based on the presence or absence of erythrocyte receptors(E) a T cell marker, acute lymphocytic leukemia (ALL), can be divided into E+ALL and E-ALL. We studied cell surface antigens on blasts from 12 children with untreated ALL: eight with E-ALL and four with E+ALL. Heterologous antisera were raised against thymus cells, E+ and E-ALL blasts, appropriately absorbed and tested by immunofluorescence and a radiolabeled antibody assay with normal and leukemic lymphoid cells. By both methods, anti-thymus and anti-E+ALL sera reacted with human thymocytes. Specific binding of anti-E+ALL serum to T antigens was indicated by the fact that a single absorption with thymocytes abolished its binding to allogenic thymocytes, and the reactivity of anti-E+ALL serum with thymus, blood and bone marrow lymphocytes was similar to that of anti-thymus serum. After exhaustive absorption with blood leukocytes, anti-E+ALL and E-ALL sera were negative against normal lymphocytes and bone marrow cells from children with ALL in remission. Anti-thymus and anti-E+ALL sera reacted with blasts from patients with E+ALL, but not with E-ALL. In contrast, anti-E+ALL serum reacted with 40 to 96% of blasts from all children with E-ALL, whereas of the four patients with E+ALL, two were negative and two had the lowest percentage of immunofluorescent cells (10 to 22%). These results were confirmed with the radiolabeled antibody assay. Patients with active E-ALL had cells bearing E-ALL antigen(s) in the peripheral blood and bone marrow, but the number of immunofluorescent cells was lower in blood. Cells reactive with anti-E-ALL serum did not react with thymus cells, blood lymphocytes, remission bone marrow cells, Raji cells, PWM and PHA-induced blasts and CLL cells bearing mIg (uk). These data suggest that the antigen detected on E-ALL blasts by anti-E-ALL serum is neither a HLA-related nor a cell differentiation antigen. Thus, by using antiserum to E+ALL blasts, we have confirmed the presence of a T cell-specific antigen(s) on E+ALL cells. This antiserum did not recognize other leukemia-associated antigens common to E+ and E-ALL. We have also demonstrated an antigen(s) which is regularly expressed on E-ALL blasts and is either not detectable or is present in a lower proportion of E+ALL blasts.
根据T细胞标志物红细胞受体（E）的有无，急性淋巴细胞白血病（ALL）可分为E⁺ALL和E⁻ALL。我们研究了12例未经治疗的ALL患儿原始细胞的细胞表面抗原：8例为E⁻ALL，4例为E⁺ALL。用胸腺细胞、E⁺ALL和E⁻ALL原始细胞制备异种抗血清，经适当吸收后，通过免疫荧光以及用正常和白血病淋巴样细胞进行的放射性标记抗体测定进行检测。两种方法中，抗胸腺和抗E⁺ALL血清均与人类胸腺细胞发生反应。抗E⁺ALL血清与T抗原的特异性结合表现为用胸腺细胞单次吸收可消除其与同种异体胸腺细胞的结合，且抗E⁺ALL血清与胸腺、血液和骨髓淋巴细胞的反应性与抗胸腺血清相似。用血液白细胞彻底吸收后，抗E⁺ALL和抗E⁻ALL血清对ALL缓解期患儿的正常淋巴细胞和骨髓细胞呈阴性反应。抗胸腺和抗E⁺ALL血清与E⁺ALL患者的原始细胞发生反应，但与E⁻ALL患者的原始细胞不发生反应。相反，抗E⁺ALL血清与所有E⁻ALL患儿中40%至96%的原始细胞发生反应，而在4例E⁺ALL患者中，2例呈阴性，2例免疫荧光细胞百分比最低（10%至22%）。放射性标记抗体测定证实了这些结果。活动性E⁻ALL患者外周血和骨髓中有携带E⁻ALL抗原的细胞，但血液中免疫荧光细胞数量较少。与抗E⁻ALL血清反应的细胞不与胸腺细胞、血液淋巴细胞、缓解期骨髓细胞、Raji细胞、PWM和PHA诱导的原始细胞以及携带mIg（uk）的慢性淋巴细胞白血病（CLL）细胞发生反应。这些数据表明，抗E⁻ALL血清在E⁻ALL原始细胞上检测到的抗原既不是与HLA相关的抗原，也不是细胞分化抗原。因此，通过使用抗E⁺ALL原始细胞的抗血清，我们证实了E⁺ALL细胞上存在T细胞特异性抗原。该抗血清未识别E⁺ALL和E⁻ALL共有的其他白血病相关抗原。我们还证明了一种在E⁻ALL原始细胞上经常表达的抗原，在E⁺ALL原始细胞中要么检测不到，要么所占比例较低。
